MEVION S250i Selected by Jinshazhou Hospital to Equip New Proton Therapy Center in Guangzhou, China
Mevion Medical Systems is pleased to announce it has signed an agreement for the sale of a MEVION S250i Proton Therapy System® with HYPERSCAN® Pencil Beam Scanning to Jinshazhou Hospital of Guangzhou University of Chinese Medicine. This will be the first compact proton therapy system in the Guangdong-Hong Kong-Macau Greater Bay Area. The signing ceremony was held on December 20, 2019, at Jinshazhou Hospital and joined by nearly one hundred Chinese and international radiation oncology experts and hospital executives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200116005186/en/
Wensheng Liu, President of Jinshazhou Hospital (right), and Lawrence Yuan Tian, Ph.D., Chairman of Mevion Medical Systems, at the purchase agreement signing ceremony. (Photo: Business Wire)
The MEVION S250i system will be incorporated into the hospital’s world-class International Cancer Center in Guangzhou and is expected to begin treatment in 2021. Guangzhou is the capital city of the Guangdong province, which has a population of over one hundred million. The International Cancer Center is a joint effort between Jinshazhou Hospital and the ICON Group, Australia’s leading cancer care service provider. Led by Yang Wang, Ph.D., an internationally renowned medical physicist and the Vice President of Jinshazhou Hospital and Director of the International Cancer Center, the Center is equipped with cutting-edge medical technologies and an experienced medical team at the forefront of the cancer research. The University of Wollongong in Australia will also collaborate with the Center to provide medical physics training and education.
Proton therapy is an advanced form of radiation therapy that reduces unnecessary radiation dose to healthy tissue and prevents complications and secondary cancers. Mevion’s leading HYPERSCAN Pencil Beam Scanning technology further enhances these benefits with a faster and sharper dose delivery, which can be collimated layer-by-layer to provide a more precise and conformal dose to the tumor.
“We are pleased to be partnering with Mevion to make proton therapy available to benefit cancer patients in South China,” said Wensheng Liu, President of Jinshazhou Hospital. “MEVION S250i system is the most advanced proton therapy system available today and represents the best overall proton therapy solution. Its addition will position Jinshazhou Hospital as a world-class radiation therapy center. We look forward to elevating our cancer treatment, research capabilities, and medical education to the next level with protons.”
“It is exciting that the International Cancer Center and ICON Group will be able to utilize the most advanced proton technology provided by Mevion,” said Mark Middleton, CEO of ICON Group. “I believe the collaboration between Jinshazhou Hospital, ICON Group, Mevion, and University of Wollongong will have a bright future.”
“Mevion pioneered the world’s first compact single-room proton therapy system,” said Lawrence Yuan Tian, Ph.D., Chairman of Mevion Medical Systems. “Since its founding, Mevion has been leading the revolution of compact proton therapy as this advanced cancer treating technology gains widespread global adoption. We are proud to partner with Jinshazhou Hospital and ICON Group to bring the most precise radiation therapy to patients in the Greater Bay Area and beyond.”
The sale of a MEVION S250i system to Jinshazhou represents another concrete step in Mevion’s ambitious and ongoing expansion in China and the APAC region. "Combining the technical advantages of our product with a strong China team, Mevion is well-positioned to tap the fast-growing proton market in China,” said Tina Yu, Ph.D., CEO of Mevion Medical Systems. “Elite medical institutions in China have signed framework agreements with us in the past year, and we are on track to deliver our accelerator to Allcure Kangtai in 2020. Our collaboration with Jinshazhou Hospital marks another significant milestone in Mevion’s global growth."
About Mevion Medical Systems
Mevion Medical Systems, Inc. is the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients. Mevion is based in Littleton, Massachusetts, with a presence in Europe and Asia. For more information, please visit www.mevion.com.
Mevion Medical Systems
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Conquest Invests in 5 Greenfield Onshore Wind Parks Totalizing 43MW in the Flanders Region24.1.2020 15:37:00 EET | Press release
Conquest, acting through the Conquest Sustainable Infrastructure fund, announced the transaction was closed after an exclusive agreement had been reached with ENGIE Electrabel. Conquest acquires 51% of a portfolio expected to provide 111 GWh per annum of renewable power representing the annual electricity consumption of about 32,000 Belgian homes from early 2021 onwards. The projects benefit from 15 to 20-year green certificates local remuneration schemes, and thus generate yearly secured revenues. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200124005221/en/ Credit: Electrabel While the energy and digital transitions continue to drive the infrastructure sector, Conquest keeps building its diversified sustainable real asset portfolio in Western European markets. The success lies in years of collaboration and long-lasting partnerships with fellow industry experts who can notably facilitate access to new growth opportunities
Fluence Expands EMEA Footprint with Horticulture Partners in Papenburg, Germany24.1.2020 14:00:00 EET | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and agriculture production, announced today it is expanding its presence in the Emsland region of Germany through partnerships with growers and other horticulture specialists operating out of Papenburg. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200124005109/en/ Friedrich Schulz’s 5.5 hectare farm—which grows herbs year-round in addition to lettuce, peppers and chives—utilizing VYPR 2p fixtures. (Photo: Business Wire) Given Papenburg’s decades-long history of attracting horticulture experts, Fluence’s innovative lighting solutions for horticulture are a natural fit for the region’s tomato, cucumber, leafy greens and herb growers. Forging connections with Papenburg’s horticultural leaders Elektro Evers, an engineering firm specializing in greenhouse technology, is Fluence’s exclusive systems integrator
HCL Technologies Honors Global Goodwill Champions at the 2020 World Economic Forum in Davos24.1.2020 12:47:00 EET | Press release
HCL Technologies (HCL), a leading global technology company, today presented its Wave Maker Awards 2020, commemorating global goodwill champions from around the world. The award ceremony, which was held at the HCL Pavilion in Davos, celebrated organizations and individuals passionately committed to such noble causes as diversity & inclusion, education & community upliftment, environment & sustainability, and technology for change. Special guest at the awards was Australian cricket legend Glenn McGrath, who is also founder of the McGrath Foundation, which provides support for Australian women diagnosed with breast cancer and their families. The award recipients were; Lois Auta, Founder and Executive Director of Cedar Seed Foundation, which supports persons with disabilities to participate in all aspects of life; Chido Govera, Founder and Director of The Future of Hope Foundation (TFoHF), which supports marginal and vulnerable members of society through entrepreneurial and self-developme
Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria24.1.2020 09:00:00 EET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the decision to pause dosing patients in the global Phase III (PVO-1A-301) study designed to evaluate the efficacy and safety of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), as well as the ongoing Phase II (PVO-1A-202/204) extension studies. In both the Phase III and Phase II extension studies, palovarotene is dosed both chronically (daily) and episodically (during flare-ups). The decision to pause dosing patients in the trial is based on results of a futility analysis reviewed by the Independent Data Monitoring Committee (IDMC) as part of the prespecified interim analysis. The results of a futility analysis indicated that the Phase III FOP trial was unlikely to meet its primary efficacy endpoint (annualized change in new HO volume as compared with Natural History Studyi) upon completion. Despite the results of the prespecified interim analysis, signals of encouraging therapeutic activity w
Amazentis Announces the Launch of Timeline™ Cellular Nutrition at the World Economic Forum in Davos23.1.2020 23:56:00 EET | Press release
Amazentis announces the debut of Timeline, a next generation nutrition product designed to promote healthy aging, as part of the Swiss Food & Nutrition Valley in the House of Switzerland at the World Economic Forum in Davos, Switzerland. Given the increase in the aging population globally -- according to a 2019 Deutsche Bank study, there are more people on Earth older than sixty five than younger than five for the first time -- it is imperative for consumers to take proactive measures to maintain a high quality of life, for as long as they live. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200123005820/en/ (Photo: Business Wire) Timeline contains the proprietary nutrient Mitopure™, a highly pure form of Urolithin A. After a decade of rigorous research by leading scientists around the world, Mitopure has been shown to help counter age-associated cellular and muscular decline by revitalizing the mitochondria, the powerplants
Lionbridge Names Corinne Saunders as Managing Director, EMEA23.1.2020 21:00:00 EET | Press release
Today, Lionbridge, a global leader in localization and data training services, announced that former Wolters Kluwer executive Corinne Saunders has joined the company as managing director of EMEA. Lionbridge currently has 51 offices in 26 countries around the world; Saunders will oversee EMEA sales, account management, and marketing operations. “Europe represents a large portion of our overall business and will continue to be a growth area for our AI and localization businesses. I am very happy that Corinne is coming onboard to lead our efforts across EMEA,” says Lionbridge Chief Executive Officer John Fennelly. “Throughout her career, she’s shown an exceptional ability for driving innovation and understanding customer needs.” While at Wolters Kluwer, Saunders served as chief executive officer for emerging and developing markets. Saunders will work from Brussels, Belgium. About Lionbridge Lionbridge partners with brands to break barriers and build bridges all over the world. For more th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom